Linked Life Data

11476123

Source:http://linkedlifedata.com/resource/pubmed/id/11476123

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-7-30
pubmed:abstractText
There are no rapid-acting intramuscular formulations of atypical antipsychotics available for quickly calming an agitated patient with bipolar disorder. In this study, 201 agitated patients with bipolar mania were randomly assigned to receive one to three injections of the atypical antipsychotic olanzapine (10 mg, first two injections; 5 mg, third injection), the benzodiazepine lorazepam (2 mg, first two injections; 1 mg, third injection), or placebo (placebo, first two injections; olanzapine, 10 mg, third injection) within a 24-hour period. Agitation was measured at baseline, every 30 minutes for the first 2 hours, and at 24 hours after the first injection using the Positive and Negative Syndrome Scale-Excited Component subscale and two additional agitation scales. At 2 hours after the first injection, patients treated with olanzapine showed a significantly greater reduction in scores on all agitation scales compared with patients treated with either placebo or lorazepam. At 24 hours after the first injection, olanzapine remained statistically superior to placebo in reducing agitation in patients with acute mania, whereas patients treated with lorazepam were not significantly different from those treated with placebo or olanzapine. Furthermore, no significant differences among the three treatment groups were observed in safety measures, including treatment-emergent extrapyramidal symptoms, the incidence of acute dystonia, or QTc interval changes. These findings suggest that intramuscular olanzapine is a safe and effective treatment for reducing acute agitation in patients with bipolar mania.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0271-0749
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
389-97
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11476123-Adult, pubmed-meshheading:11476123-Affect, pubmed-meshheading:11476123-Anti-Anxiety Agents, pubmed-meshheading:11476123-Antipsychotic Agents, pubmed-meshheading:11476123-Benzodiazepines, pubmed-meshheading:11476123-Bipolar Disorder, pubmed-meshheading:11476123-Cholinergic Antagonists, pubmed-meshheading:11476123-Double-Blind Method, pubmed-meshheading:11476123-Female, pubmed-meshheading:11476123-Heart Rate, pubmed-meshheading:11476123-Humans, pubmed-meshheading:11476123-Injections, Intramuscular, pubmed-meshheading:11476123-Lorazepam, pubmed-meshheading:11476123-Male, pubmed-meshheading:11476123-Middle Aged, pubmed-meshheading:11476123-Pirenzepine, pubmed-meshheading:11476123-Psychiatric Status Rating Scales, pubmed-meshheading:11476123-Psychomotor Agitation, pubmed-meshheading:11476123-Treatment Outcome
pubmed:year
2001
pubmed:articleTitle
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
pubmed:affiliation
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study